{
    "nctId": "NCT00320710",
    "briefTitle": "Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer",
    "officialTitle": "A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 416,
    "primaryOutcomeMeasure": "Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nFemale patients \u2265 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa\u00ae, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;\n\nExclusion Criteria:\n\nAbnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.\n\nRecent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).\n\nDiagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of bone).\n\nKnown hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days prior to randomization.\n\nOther protocol-defined exclusion criteria may have applied.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}